Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Individuals with hemophilia A require frequent infusion of preparations of coagulation factor VIII. The activity of factor VIII (FVIII) as a cofactor for factor IXa in the coagulation cascade is limited by its instability after activation by thrombin. Activation of FVIII occurs through proteolytic cleavage and generates an unstable FVIII heterotrimer that is subject to rapid dissociation of its subunits. In addition, further proteolytic cleavage by thrombin, factor Xa, factor IXa, and activated protein C can lead to inactivation. We have engineered and characterized a FVIII protein, IR8, that has enhanced in vitro stability of FVIII activity due to resistance to subunit dissociation and proteolytic inactivation. FVIII was genetically engineered by deletion of residues 794-1689 so that the A2 domain is covalently attached to the light chain. Missense mutations at thrombin and activated protein C inactivation cleavage sites provided resistance to proteolysis, resulting in a single-chain protein that has maximal activity after a single cleavage after arginine-372. The specific activity of partially purified protein produced in transfected COS-1 monkey cells was 5-fold higher than wild-type (WT) FVIII. Whereas WT FVIII was inactivated by thrombin after 10 min in vitro , IR8 still retained 38% of peak activity after 4 hr. Whereas binding of IR8 to von Willebrand factor (vWF) was reduced 10-fold compared with WT FVIII, in the presence of an anti-light chain antibody, ESH8, binding of IR8 to vWF increased 5-fold. These results demonstrate that residues 1690–2332 of FVIII are sufficient to support high-affinity vWF binding. Whereas ESH8 inhibited WT factor VIII activity, IR8 retained its activity in the presence of ESH8. We propose that resistance to A2 subunit dissociation abrogates inhibition by the ESH8 antibody. The stable FVIIIa described here provides the opportunity to study the activated form of this critical coagulation factor and demonstrates that proteins can be improved by rationale design through genetic engineering technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII
Pittman, D., Alderman, E., Tomkinson, K., Wang, J., Giles, A., & Kaufman, R. (1993) · Blood · doi:10.1182/blood.v81.11.2925.2925 · Cited by 268
Self-citation
Cited by
The Life Cycle of Coagulation Factor VIII in View of Its Structure and Function
Lenting, P. J., van Mourik, J. A., & Mertens, K. (1998) · Blood · doi:10.1182/blood.v92.11.3983 · Cited by 451
Yao, N., Reichert, P., Taremi, S. S., Prosise, W. W., & Weber, P. C. (1999) · Structure · doi:10.1016/s0969-2126(00)80025-8 · Cited by 391
Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy
Samelson-Jones, B. J., & Arruda, V. R. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.12.007 · Cited by 58
Expression of factor VIII in recombinant and transgenic systems
Soukharev, S., Hammond, D., Ananyeva, N. M., Anderson, J. A. M., Hauser, C. A. E., Pipe, S., & Saenko, E. L. (2002) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2002.0508 · Cited by 35
Self-citationKashiwakura, Y., Nakajima, Y., Horinaka, K., Lopes, T. J. S., Furuta, Y., Yamaguchi, Y., Baatartsogt, N., Hayakawa, M., Katakai, Y., Uchiyama, S., et al. (2026) · Blood · doi:10.1182/blood.2025028481 · Cited by 3
Metadata
- Authors
- Pipe, S. W., & Kaufman, R. J.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1997-10-28
- Volume
- 94
- Issue
- 22
- Pages
- 11851-11856
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2037949785
- Cited by
- 125
- References
- 1
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. https://app.cochat.ai/papers/10.1073/pnas.94.22.11851
- The paper
- Pipe, S. W., & Kaufman, R. J. (1997). Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.94.22.11851
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.